We’re excited to be attending ImmunoMark Summit 2026 on March 5th - 6th in London, UK. Immunotherapies are reshaping the landscape of cancer care, making the identification and validation of resilient biomarkers central to the realization of precision medicine. Come connect with our team and learn about how Biocytogen is accelerating the development of next-generation immunotherapies.
What is ImmunoMark Summit 2026?
ImmunoMark 2026 will bring together global leaders and innovators in immuno-oncology (IO) and biomarker discovery, for a two day strategic forum. The summit will focus on the latest advances in IO science, biomarker identification, companion diagnostics, translational research, clinical validation, and changes in regulations. This is a great opportunity to gain actionable insights, form meaningful collaborations, and bridge the transition from drug discovery to delivery.
Event Overview
Date: March 5th - 6th, 2026
Venue: DoubleTree by Hilton London Tower of London, 7 Pepys St, London 3C3N 4AF, UK
Event Schedule
For more information, please refer to the event website here.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in London!
